GWP
VKTX icon

Gen-Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

Gen-Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228 Hold
7
– – ﹤0.01% 711
2025
Q4 		$246 Hold
7
– – ﹤0.01% 676
2025
Q3 		$184 Hold
7
– – ﹤0.01% 675
2025
Q2 		$186 Hold
7
– – ﹤0.01% 632
2025
Q1 		$169 Hold
7
– – ﹤0.01% 609
2024
Q4 		$282 Buy
+7
New +$399 ﹤0.01% 635

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Gen-Wealth Partners's VKTX Position: Q1 2026 in Review

Gen-Wealth Partners held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 7 shares worth $228. The position accounts for ﹤0.01% of the portfolio, ranked #711.

Gen-Wealth Partners first reported a position in VKTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $282 in Q4 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Gen-Wealth Partners held 7 shares of Viking Therapeutics worth $228 as of Q1 2026.
  • Gen-Wealth Partners left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #711 holding.
  • Gen-Wealth Partners first reported a position in Viking Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Gen-Wealth Partners's Viking Therapeutics position peaked at $282 in Q4 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.